José Luis Sandoval1,2, Allan Relecom2, Cyril Ducros3, Jean-Luc Bulliard4, Beatrice Arzel5, Idris Guessous1. 1. Unit of Population Epidemiology, Division of Primary Care Medicine, Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland. 2. Department of Oncology, Geneva University Hospitals, Geneva, Switzerland. 3. Vaud Cancer Screening Foundation, Lausanne, Switzerland. 4. Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland. 5. Geneva Cancer Screening Foundation, Geneva, Switzerland.
Abstract
OBJECTIVES: Fecal blood testing is a noninvasive alternative to colonoscopy for colorectal cancer (CRC) screening and is preferred by a substantial proportion of individuals. However, participant-related determinants of the choice of screening method, particularly up-to-date screening status, remain less studied. We aimed to determine if up-to-date screening status was related to choosing a fecal blood test over colonoscopy. SETTING: Participants in the population-based cross-sectional survey study Bus Santé in Geneva, Switzerland - aged 50-69 years. DESIGN: Cross-sectional survey study using mailed questionnaires inquiring about CRC screening method of choice after providing information on advantages and disadvantages of both screening methods. We used multivariable logistic regression models to determine the association between up-to-date CRC screening status and choosing fecal blood testing. KEY RESULTS: We included 1,227 participants. Thirty-eight percent of participants did not have up-to-date CRC screening. Overall, colonoscopy (54.9%) was preferred to fecal blood testing (45.1%) (p < 0.001) as screening method of choice. However, screening method choices differed between those with (65.6% colonoscopy and 34.4% fecal blood testing) and without up-to-date CRC screening (36.5% colonoscopy and 63.5% fecal blood testing). Not having up-to-date CRC screening was associated with a higher probability of choosing fecal blood testing as screening method (odds ratio = 2.6 [1.9; 3.7], p < 0.001) after adjustment for the aforementioned confounders. CONCLUSIONS: Not having up-to-date screening was independently associated with fecal blood testing as the preferred method for CRC screening. Proposing this method to this subpopulation, in a context of shared decision, could potentially increase screening uptake in settings where it is already high.
OBJECTIVES: Fecal blood testing is a noninvasive alternative to colonoscopy for colorectal cancer (CRC) screening and is preferred by a substantial proportion of individuals. However, participant-related determinants of the choice of screening method, particularly up-to-date screening status, remain less studied. We aimed to determine if up-to-date screening status was related to choosing a fecal blood test over colonoscopy. SETTING: Participants in the population-based cross-sectional survey study Bus Santé in Geneva, Switzerland - aged 50-69 years. DESIGN: Cross-sectional survey study using mailed questionnaires inquiring about CRC screening method of choice after providing information on advantages and disadvantages of both screening methods. We used multivariable logistic regression models to determine the association between up-to-date CRC screening status and choosing fecal blood testing. KEY RESULTS: We included 1,227 participants. Thirty-eight percent of participants did not have up-to-date CRC screening. Overall, colonoscopy (54.9%) was preferred to fecal blood testing (45.1%) (p < 0.001) as screening method of choice. However, screening method choices differed between those with (65.6% colonoscopy and 34.4% fecal blood testing) and without up-to-date CRC screening (36.5% colonoscopy and 63.5% fecal blood testing). Not having up-to-date CRC screening was associated with a higher probability of choosing fecal blood testing as screening method (odds ratio = 2.6 [1.9; 3.7], p < 0.001) after adjustment for the aforementioned confounders. CONCLUSIONS: Not having up-to-date screening was independently associated with fecal blood testing as the preferred method for CRC screening. Proposing this method to this subpopulation, in a context of shared decision, could potentially increase screening uptake in settings where it is already high.
Authors: Idris Guessous; Chiranjeev Dash; Pauline Lapin; Mary Doroshenk; Robert A Smith; Carrie N Klabunde Journal: Prev Med Date: 2009-12-16 Impact factor: 4.018
Authors: Ann C DeBourcy; Scott Lichtenberger; Susanne Felton; Kiel T Butterfield; Dennis J Ahnen; Thomas D Denberg Journal: J Gen Intern Med Date: 2007-12-21 Impact factor: 5.128
Authors: Paul C Schroy; Karen M Emmons; Ellen Peters; Julie T Glick; Patricia A Robinson; Maria A Lydotes; Shamini R Mylvaganam; Alison M Coe; Clara A Chen; Christine E Chaisson; Michael P Pignone; Marianne N Prout; Peter K Davidson; Timothy C Heeren Journal: Am J Prev Med Date: 2012-12 Impact factor: 5.043